Journeying to Ixtlan: Ethics of Psychedelic Medicine and Research for Alzheimer's Disease and Related Dementias.
AJOB neuroscience – January 01, 2023
Source: PubMed
Summary
Psychedelic medicine shows promise for addressing psychiatric symptoms in Alzheimer's disease and related dementias, yet remains unapproved for treatment. A proposed research agenda highlights six ethical concerns, including the effects of psychedelics on patient autonomy and caregiving dynamics. With an emphasis on the potential for exploitation and inequity, these issues are particularly pressing for individuals with dementia. Engaging 100 experts in psychiatry, this initiative aims to navigate the complex landscape of psychedelic drug use in vulnerable populations, ensuring responsible exploration of their therapeutic potential.
Abstract
In this paper, we examine the case of psychedelic medicine for Alzheimer's disease and related dementias (AD/ADRD). These "mind-altering" drugs are not currently offered as treatments to persons with AD/ADRD, though there is growing interest in their use to treat underlying causes and associated psychiatric symptoms. We present a research agenda for examining the ethics of psychedelic medicine and research involving persons living with AD/ADRD, and offer preliminary analyses of six ethical issues: the impact of psychedelics on autonomy and consent; the impact of "ego dissolution" on persons experiencing a pathology of self; how psychedelics might impact caregiving; the potential exploitation of patient desperation; institutional review boards' orientation to psychedelic research; and methods to mitigate inequity. These ethical issues are magnified for AD/ADRD but bear broader relevance to psychedelic medicine and research in other clinical populations.